(Q28445153)

English

CDKN2A Loss

genetic variant

Loss

In more languages

Statements

Loss Of Function Variant

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/554

human chromosome 9

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/554

21967752

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/554

21994623

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/554

biological variant of

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/554

positive therapeutic predictor for

determination method

CIViC evidence level D

CIViC 3-star trust rating

medical condition treated

renal cell carcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1373

PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity

determination method

CIViC evidence level D

CIViC 3-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1375

Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines

determination method

CIViC evidence level D

CIViC 3-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1377

Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer

palbociclib / letrozole combination therapy

determination method

CIViC evidence level C

CIViC 3-star trust rating

medical condition treated

Her2-receptor negative breast cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1765

Does CDKN2A loss predict palbociclib benefit?

determination method

CIViC evidence level D

CIViC 2-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1879

Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model.

determination method

CIViC evidence level D

CIViC 2-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1879

Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model.

determination method

CIViC evidence level D

CIViC 2-star trust rating

medical condition treated

dermatofibrosarcoma protuberans

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1881

CDKN2A/p16 Loss Implicates CDK4 as a Therapeutic Target in Imatinib-Resistant Dermatofibrosarcoma Protuberans.

negative prognostic predictor for

acute lymphocytic leukemia

determination method

CIViC evidence level B

CIViC 4-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/7986

Prognostic significance of CDKN2A/B deletions in acute lymphoblastic leukaemia: a meta-analysis

Identifiers

CIViC variant ID

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/554

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28445153&oldid=2014802380"